Business Wire

KAZAKHSTAN-MOJ

18.11.2021 10:47:12 CET | Business Wire | Press release

Share
Republic of Kazakhstan defeats Statis -- Belgium Court of Appeal conclusively determines Statis defrauded arbitral tribunal and “deliberately misled” Swedish annulment courts -- reverses recognition and enforcement of USD 530 million arbitral award

A ground-breaking victory has been achieved by the Republic of Kazakhstan in its long-running efforts to bring to justice the Moldovan oligarchs Anatolie Stati and Gabriel Stati (“Statis ”).

On 16 November 2021, the Belgian Appeal Court conclusively determined that the Statis engaged in a massive fraudulent scheme that defrauded not only the arbitral tribunal but also the Swedish courts during the prior annulment proceedings. This fraudulent scheme, the court held, had a direct impact on the arbitral tribunal’s findings both on liability and damages. On that basis, the Court of Appeal completely reversed a lower court order that had granted recognition and enforcement to the Statis’ USD 530 million arbitral award (“the Award ”).

The law firm of King & Spalding represented the Statis in the arbitral proceedings and is coordinating their global efforts to recognize and enforce the fraudulent arbitral award, including in Sweden and Belgium.

As previously reported, the Statis obtained an ex parte order in December 2017 granting exequatur to the Award, which was subsequently confirmed by an order of the Belgium Court of First Instance in December 2019. However, both of these orders were based on a limited factual record which did not include the new evidence of the Statis’ fraud.

In November 2020, the Brussels Court of Appeal in Belgium (“the Court of Appeal ”) granted the Republic’s request to present its full fraud case, over the Statis’ objections.

Now, the Court of Appeal has validated the Republic’s case and confirmed the Republic’s long-standing position – that the Statis engaged in a massive fraudulent scheme, and that as a result the Award should not be recognized or enforced.

This decision by the Court of Appeal will result in a lifting of the attachment that the Statis have obtained over $530 million belonging to the National Fund of Kazakhstan, which is held by The Bank of New York Mellon.

Kazakhstan’s Minister of Justice Marat Beketayev commented as follows:

"We welcome this landmark judgment in the Republic’s favour against the Statis and their accomplices. After thoroughly analyzing all the available evidence, the Court of Appeal confirmed that the Statis committed fraud on our nation, their auditors (KPMG), the arbitral tribunal and the Swedish annulment courts. The judgment has grave implications not only for the Statis but also their professional advisers. It should serve as a point of 'no return' for those who are still aiding and abetting the Statis in their illegal schemes. The Ministry of Justice is committed to continue defending the Republic's interests against the Statis' fraudulent campaign. "

The full press release can be found here: https://kzarbitration.com/republic-of-kazakhstan-defeats-statis-belgium-court-of-appeal-conclusively-determines-statis-defrauded-arbitral-tribunal-and-deliberately-misled-swedish-annulment-courts/ .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release

A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye